Key result
Cardioembolic stroke is linked to higher serum SDF-1a levels than large vessel atherosclerotic stroke.
Why the study?
High throughput technologies provide new opportunities to further investigate the pathophysiology of ischemic strokes by evaluating potential associations between etiologic subtypes and blood-based proteins.
Are there associations between etiologic subtypes of ischemic stroke and circulating inflammation biomarkers?
Cross-Sectional (n=364)
Are there associations between etiologic subtypes of ischemic stroke and circulating inflammation biomarkers?
Different ischemic stroke etiologies are associated with distinct profiles of circulating inflammation biomarkers, such as higher SDF-1a in cardioembolic stroke.
Answers are grounded in this paper and cite their sources.
Supports distinct inflammatory profiles by stroke subtype; hypothesis-generating for SDF-1a in etiologic classification.
Background High throughput technologies provide new opportunities to further investigate the pathophysiology of ischemic strokes. The present cross‐sectional study aimed to evaluate potential associations between the etiologic subtypes of ischemic stroke and blood‐based proteins. Methods We investigated the associations between ischemic stroke subtypes and a panel of circulating inflammation biomarkers in 364 patients included in the Stroke Cohort Augsburg (SCHANA). Stroke etiologies were categorized according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification. Serum concentrations of 52 biomarkers were measured using the Bio‐Plex Pro™ Human Cytokine Screening Panel, ICAM‐1 set and VCAM‐1 set, plus the Pro™ Human TH17 cytokine sCD40L set and IL31 set (all Bio‐Rad, USA). Multivariable linear regression models were used to examine associations. Point estimates were calculated as the mean difference in ‐standardized cytokine levels on the log 2 ‐scale. Results Stromal‐cell‐derived‐factor 1 alpha (SDF‐1a) showed significantly higher serum levels in cardioembolic compared with large vessel atherosclerotic stroke ( β = 0.48; 95% CI 0.22; 0.75; P adj = 0.036). Significantly lower levels of interleukin‐6 (IL‐6) ( β = −0.53; 95% CI −0.84; −0.23; P adj = 0.036) and macrophage migration inhibitory factor (MIF) ( β = −0.52; 95% CI −0.84; −0.21; P adj = 0.043) were found in the small vessel versus large vessel stroke subtype. Conclusions Immune dysregulations observed in different stroke subtypes might help uncover pathophysiological mechanisms of the disease. Further studies are needed to validate identified biomarkers in diverse study populations before they can potentially be used in clinical practice to further improve stroke management and patient outcomes.
No takes yet. Share an insight, caveat, or question.
Meisinger et al. (2023) conducted a cross-sectional in Acute ischemic stroke (n=364). Circulating inflammation biomarkers vs. Stroke etiologic subtypes (TOAST classification) was evaluated on Associations between ischemic stroke subtypes and circulating inflammation biomarkers (β 0.48, 95% CI 0.22-0.75, p=0.036). Cardioembolic stroke was associated with higher serum levels of SDF-1a compared to large vessel atherosclerotic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: